The Nobel Assembly at Sweden's Karolinska Institute announced Monday that Karl Deisseroth, Peter Hegemann, and Georg Nagel have won the 2026 Nobel Prize in Physiology or Medicine for their discoveries concerning light-gated ion channels and optogenetics. Deisseroth, 54, is a professor at Stanford University and researcher with the Howard Hughes Medical Institute in California. Hegemann, 71, is a professor at Humboldt University of Berlin, and Nagel, 73, is based at the University of Würzburg in Germany. The two German scientists conducted their foundational research at Max Planck institutes in Martinsried and Frankfurt.
Optogenetics is a technique that fuses optics, molecular genetics, and neurobiology to control living neural circuits using pulses of laser light. The method allows scientists to switch individual nerve cells on or off with precision, enabling them to establish direct causal relationships between specific neurons and behaviors, emotions, memories, and diseases. This represents a fundamental shift from previous neuroscience approaches, which could only record brain activity or correlate regional activation with mental states but could not pinpoint causality at the level of specific neural circuits.
The scientific foundation for optogenetics began with basic biological research into single-celled organisms. In the early 2000s, Hegemann investigated how the green alga Chlamydomonas reinhardtii senses light and swims toward it. Collaborating with biophysicist Georg Nagel, he discovered a family of membrane proteins called channelrhodopsins. These proteins function as light receptors and ion channels combined in a single protein. When exposed to blue light, a channel opens within milliseconds, allowing positively charged ions—primarily sodium and calcium—to flow into the cell and generate an electrical impulse. Hegemann and Nagel demonstrated that inserting this protein into other cell types made those cells light-sensitive as well.
Karl Deisseroth recognized the potential of this discovery for neuroscience. Knowing that brain cells communicate through rapid electrical spikes driven by sodium ion influxes, he theorized that channelrhodopsin could serve as a light-controlled switch for mammalian neurons. In a landmark 2005 breakthrough, Deisseroth and his team successfully introduced the genetic sequence for channelrhodopsin-2 into cultured rat neurons using viral vectors. Brief flashes of blue light caused individual neurons to fire synchronized action potentials with millisecond precision. By 2007, Deisseroth had overcome major bioengineering challenges to deploy the technique in the brains of living, awake, and freely moving animals using thin optical fibers to deliver light deep into brain tissue.
Thomas Perlmann, Secretary-General of the Nobel Assembly at Karolinska Institutet, stated that optogenetics "makes it possible to switch on, or off, the activity of individual nerve cells in a living brain." Anna Wedell, a member of the Nobel Committee for Physiology or Medicine, said the discovery had opened a new era in neuroscience. "For the first time we can actually start to understand how the brain processes information and how different neurons interact across the brain," she said. The technique has revealed how specific brain circuits govern behaviors such as eating, sociability, and aggression, and has illuminated neurological and psychiatric conditions including Parkinson's disease, epilepsy, depression, addiction, and dementia.
While optogenetics remains primarily a research tool, early clinical applications have emerged. Researchers have used the technique to partially restore sight in patients with retinitis pigmentosa, an inherited disease that destroys light-sensing cells in the eye. In these trials, patients wear special goggles that convert visual information into light signals directed at the retina. DNA encoding light-sensing proteins is injected into retinal neurons, allowing them to activate and send electrical signals to the brain when exposed to light, bypassing the damaged cells. Several clinical trials for this application are currently underway, along with research into retinal chip implants.
The three laureates will share the prize money of 12 million Swedish kronor equally. According to reports, Deisseroth was asleep when he received notification of the award, saying he had "a hard time forming words" upon learning the news. The medicine prize announcement kicked off Nobel Prize week; the physics prize will be announced Tuesday, chemistry on Wednesday, and literature on Thursday, followed by the peace prize on Friday and the economics prize on October 12.
